Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Cipher Pharmaceuticals Inc T.CPH

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

    Latest News

    Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call


    Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor...


    Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results


    Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call


    Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading


    OTC Markets Group Welcomes Cipher Pharmaceuticals Inc. to OTCQX


    Cipher Pharmaceuticals Announces Change of Auditor


    Cipher Pharmaceuticals Announces Normal Course Issuer Bid


    Cipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023


    Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call


    Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid


    Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid


    Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up...


    Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico


    Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call